Inhibition of C-X-C chemokine receptor 2 (CXCR2)-mediated neutrophil recruitment as a targeted therapy in Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated lung adenocarcinoma.

抑制 C-X-C 趋化因子受体 2 (CXCR2) 介导的中性粒细胞募集作为 Kirsten 大鼠肉瘤病毒癌基因同源物 (KRAS) 突变肺腺癌的靶向治疗。

• 批准号: 428770
• 负责人: De Meo Meghan
• 金额: $ 1.27万
• 依托单位: McGill University
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-12-01 至 2020-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=428770&lang=en
• 关键词: C-X-C Chemokine Receptor 2 (Cxcr2); Cxcr2 Inhibition; Immune Checkpoint Inhibition; Immune Modulation; Immune-Mediated Cancer Regression; Kirsten Rat Sarcoma Viral Oncogene Homolog (Kras); Lung Adenocarcinoma; Neutrophil Recruitment; Targeted Therapy

"Lung cancer is the deadliest cancer. More than 50% of patients are diagnosed when their cancer has already spread to other organs. It is hard to develop drugs that specifically recognize tumour cells since the differences between tumour and normal cells

“肺癌是最致命的癌症。超过50%的患者在癌症已经扩散到其他器官时被诊断出来。由于肿瘤细胞和正常细胞之间的差异，